

Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry

Amany Elshorbagy^{1,2,*}, Antonio J. Vallejo-Vaz^{1,3,4,5}, Fotios Barkas^{1,6}, Alexander R.M. Lyons¹, Christophe A.T. Stevens¹, Kanika I. Dharmayat¹, Alberico L. Catapano^{7,8}, Tomas Freiburger^{9,10}, G. Kees Hovingh^{11,12}, Pedro Mata¹³, Frederick J. Raal¹⁴, Raul D. Santos¹⁵, Handrean Soran¹⁶, Gerald F. Watts^{17,18}, Marianne Abifadel¹⁹, Carlos A. Aguilar-Salinas^{20,21}, Khalid F. Alhabib²², Mutaz Alkhnifawi^{23,24}, Wael Almahmeed²⁵, Fahad Alnouri²⁶, Rodrigo Alonso²⁷, Khalid Al-Rasadi²⁸, Ahmad Al-Sarraf²⁹, Marcello Arca³⁰, Tester F. Ashavaid³¹, Maurizio Averna^{32,33}, Maciej Banach^{34,35,36}, Marianne Becker³⁷, Christoph J. Binder³⁸, Mafalda Bourbon^{39,40}, Liam R. Brunham⁴¹, Krzysztof Chlebus⁴², Pablo Corral⁴³, Diogo Cruz⁴⁴, Kairat Davletov⁴⁵, Olivier S. Descamps⁴⁶, Bambang Dwiputra⁴⁷, Marat Ezhov⁴⁸, Urh Groselj^{49,50}, Mariko Harada-Shiba⁵¹, Kirsten B. Holven⁵², Steve E. Humphries⁵³, Meral Kayikcioglu⁵⁴, Weerapan Khovidhunkit⁵⁵, Katarina Lalic⁵⁶, Gustavs Latkovskis⁵⁷, Ulrich Laufs⁵⁸, Evangelos Liberopoulos⁵⁹, Marcos M. Lima-Martinez⁶⁰, Vincent Maher⁶¹, A. David Marais⁶², Winfried März^{63,64,65,66}, Erkin Mirrakhimov^{67,68}, André R. Miserez^{69,70}, Olena Mitchenko⁷¹, Hapizah Nawawi⁷², Børge G. Nordestgaard⁷³, Andrie G. Panayiotou⁷⁴, György Paragh⁷⁵, Zaneta Petrulioniene⁷⁶, Belma Pojskic⁷⁷, Arman Postadzhiyan⁷⁸, Ashraf Reda⁷⁹, Željko Reiner⁸⁰, Ximena Reyes⁸¹, Fouzia Sadiq⁸², Wilson Ehidiamen Sadoh⁸³, Heribert Schunkert^{84,85}, Aleksandr B. Shek⁸⁶, Erik Stroes⁸⁷, Ta-Chen Su⁸⁸, Tavintharan Subramaniam⁸⁹, Andrey V. Susekov⁹⁰, Myra Tilney^{91,92}, Brian Tomlinson⁹³, Thanh Huong Truong⁹⁴, Alexandros D. Tselepis⁹⁵, Anne Tybjærg-Hansen⁹⁶, Alejandra Vázquez-Cárdenas⁹⁷, Margus Viigimaa⁹⁸, Branislav Vohnout⁹⁹, Shizuya Yamashita¹⁰⁰, and Kausik K. Ray¹; on behalf of the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)[†]

¹Department of Primary Care and Public Health, Imperial Centre for Cardiovascular Disease Prevention, School of Public Health, Imperial College London, White City Campus, 90 Wood Lane, London W12 0BZ, UK; ²Department of Physiology, Faculty of Medicine, University of Alexandria, Mowassat Campus, Alexandria, Egypt; ³Clinical Epidemiology and Vascular Risk, Instituto de Biomedicina de Sevilla, IBI/Hospital Universitario Virgen del Rocío/Universidad de Sevilla/CSIC, Sevilla, Spain; ⁴Faculty of Medicine, Department of Medicine, University of Seville,

* Corresponding author. Email: a.elshorbagy@imperial.ac.uk

[†] List of contributors to the data underlying the current manuscript is given in the [Supplementary Material](#).

© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Seville, Spain; ⁵Centro de Investigación Biomédica en Red (CIBER) de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain; ⁶Faculty of Medicine, Department of Internal Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece; ⁷Department of Pharmacological and Biomedical Sciences, University of Milan, Milan, Italy; ⁸Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy; ⁹Centre for Cardiovascular Surgery and Transplantation, and Medical Faculty, Masaryk University, Brno, Czech Republic; ¹⁰CarDia—National Institute for Metabolic and Cardiovascular Disease Research, Czech Republic; ¹¹Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; ¹²Novo Nordisk, Soborg, Denmark; ¹³Fundación Hipercolesterolemia Familiar, Madrid, Spain; ¹⁴Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ¹⁵Heart Institute (InCor), University of São Paulo and Hospital Israelita Albert Einstein, São Paulo, Brazil; ¹⁶Manchester University NHS Foundation Trust, Manchester, UK; ¹⁷Faculty of Health and Medical Sciences, School of Medicine, University of Western Australia, Perth, WA, Australia; ¹⁸Department of Cardiology, Lipid Disorders Clinic, Cardiometabolic Services, Royal Perth Hospital, Perth, WA, Australia; ¹⁹Faculty of Pharmacy, Laboratory of Biochemistry and Molecular Therapeutics, Saint Joseph University, Beirut, Lebanon; ²⁰Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, México; ²¹Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico; ²²Department of Cardiac Sciences, King Fahad Cardiac Centre, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia; ²³College of Pharmacy, University of Al Qadisiyah, Al Diwanayah, Iraq; ²⁴College of Medicine, University of Warith Al-Anbiya, Karbala, Iraq; ²⁵Cleveland Clinic Abu Dhabi, Heart and Vascular Institute, Abu Dhabi, United Arab Emirates; ²⁶Cardiovascular Prevention Unit, Adult Cardiology Department, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia; ²⁷Centre for Advanced Metabolic Medicine and Nutrition, Santiago, Chile; ²⁸Department of Biochemistry, College of Medicine and Health Science, Sultan Qaboos University, Muscat, Oman; ²⁹Sabah Al Ahmad Cardiac Centre, Kuwait City, Kuwait; ³⁰Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; ³¹Department of Laboratory Medicine, PD Hinduja Hospital and Medical Research Centre Mahim, Mumbai, India; ³²Department of Health Promotion Sciences, Maternal and Infantile Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy; ³³Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Palermo, Italy; ³⁴Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland; ³⁵Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland; ³⁶Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland; ³⁷Department of Pediatric Endocrinology and Diabetology, Centre hospitalier de Luxembourg, Luxembourg City, Luxembourg; ³⁸Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria; ³⁹Unidade de Investigação e Desenvolvimento, Grupo de Investigação Cardiovascular, Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal; ⁴⁰Faculty of Sciences, Biosystems and Integrative Sciences Institute (BioISI), University of Lisbon, Lisbon, Portugal; ⁴¹Departments of Medicine and Medical Genetics, Centre for Heart Lung Innovation, The University of British Columbia, Vancouver, Canada; ⁴²1st Department of Cardiology Medical University of Gdańsk, National Centre of Familial Hypercholesterolaemia in Gdańsk, Gdańsk, Poland; ⁴³Pharmacology Department, FASTA University, School of Medicine, Mar del Plata, Argentina; ⁴⁴Portuguese Atherosclerosis Society, Lisbon, Portugal; ⁴⁵Research Health Institute, Al Farabi Kazakh National University, Almaty, Kazakhstan; ⁴⁶Centres Hospitaliers Universitaires HELORA at La Louvière and University of Mons, Mons, Belgium; ⁴⁷Faculty of Medicine, Department of Cardiology and Vascular Medicine, Universitas Indonesia—Harapan Kita National Cardiovascular Center, Jakarta, Indonesia; ⁴⁸National Medical Research Centre of Cardiology of Ministry of Health of the Russian Federation, Moscow, Russia; ⁴⁹Department of Paediatric Endocrinology, Diabetes and Metabolism, University Medical Centre, University Children's Hospital Ljubljana, Ljubljana, Slovenia; ⁵⁰Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; ⁵¹Osaka Medical and Pharmaceutical University, Takatsuki, Japan; ⁵²National Advisory Unit on Familial Hypercholesterolemia, Oslo University Hospital, Oslo, Norway; ⁵³Centre for Cardiovascular Genetics, Institute for Cardiovascular Science, University College London, London, UK; ⁵⁴Department of Cardiology, Ege University Medical School, Izmir, Turkey; ⁵⁵Faculty of Medicine, Department of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand; ⁵⁶Faculty of Medicine, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University of Belgrade, Belgrade, Serbia; ⁵⁷Faculty of Medicine, Research Institute of Cardiology and Regenerative Medicine, University of Latvia, Pauls Stradins Clinical University Hospital, Riga, Latvia; ⁵⁸Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany; ⁵⁹First Department of Propaedeutic and Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; ⁶⁰Universidad de Oriente, Núcleo Bolívar, Ciudad Bolívar, Venezuela; ⁶¹Advanced Lipid Management and Research Centre (ALMAR), Tallaght University Hospital, Dublin, Ireland; ⁶²Chemical Pathology, University of Cape Town Health Science Faculty, Cape Town, South Africa; ⁶³DACH Society for the Prevention of Heart and Circulatory Diseases, Hamburg, Germany; ⁶⁴Medical Faculty Mannheim, Department of Internal Medicine, Heidelberg University, Mannheim, Germany; ⁶⁵Klinisches Institut für Medizinische und Chemische Labordiagnostik, Medizinische Universität Graz, Graz, Austria; ⁶⁶Synlab Akademie, Synlab Holding Deutschland, Mannheim and Augsburg, Germany; ⁶⁷Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan; ⁶⁸College of Medicine, Korea University, Seoul, Korea; ⁶⁹Diagene Research Institute and Swiss Society for Familial Forms of Hypercholesterolemia (SSFH), Reinach, Switzerland; ⁷⁰Faculty of Medicine, University of Basel, Basel, Switzerland; ⁷¹Department of Dyslipidaemia, Institute of Cardiology, National Academy of Medical Sciences, Kiev, Ukraine; ⁷²Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM) and Faculty of Medicine, Universiti Teknologi MARA (UiTM), Sungai Buloh, Selangor, Malaysia; ⁷³Herlev and Gentofte Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark; ⁷⁴Department of Rehabilitation Sciences, School of Health Sciences, Cyprus University of Technology, Limassol, Cyprus; ⁷⁵Faculty of Medicine, Division of Metabolic Diseases, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary; ⁷⁶Vilnius University Faculty of Medicine and Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; ⁷⁷Faculty of Medicine, Cantonal Hospital Zenica, University of Zenica, Zenica, Bosnia and Herzegovina; ⁷⁸Medical University of Sofia, Sofia, Bulgaria; ⁷⁹Faculty of Medicine, Department of Cardiology, Menoufia University, Al Minufiyah, Egypt; ⁸⁰Department of Internal Medicine, University Hospital Centre Zagreb, and School of Medicine, University of Zagreb, Zagreb, Croatia; ⁸¹GENYCO Program, Comisión Honoraria para la Salud Cardiovascular, Montevideo, Uruguay; ⁸²Directorate of Research, Shifa Tameer-e-Millat University, Islamabad, Pakistan; ⁸³Department of Child Health, University of Benin Teaching Hospital, Benin City, Nigeria; ⁸⁴Clinic for Heart and Circulatory Diseases, German Heart Centre Munich, Technical University Munich, Munich, Germany; ⁸⁵German Centre for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany; ⁸⁶Department of Coronary Heart Disease and Atherosclerosis, Republican Specialized Centre of Cardiology, Ministry of Health of Republic Uzbekistan, Tashkent, Uzbekistan; ⁸⁷Department of Vascular Medicine, D3.330, AMC, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands; ⁸⁸Departments of Environmental and Occupational Medicine, and Internal Medicine (Cardiology Division), National Taiwan University Hospital, Taipei, Taiwan; ⁸⁹Admiralty Medical Centre and Khoo Teck Puat Hospital, Yishun Health, Singapore; ⁹⁰Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation, Moscow, Russia; ⁹¹Lipid Clinic, Mater Dei Hospital, Msida, Malta; ⁹²Faculty of Medicine and Surgery, Department of Medicine, University of Malta, Msida, Malta; ⁹³Faculty of Medicine, Macau University of Science and Technology, Macau, China; ⁹⁴Faculty of Medicine, Phenikaa University, Vietnam Atherosclerosis Society, Hanoi, Vietnam; ⁹⁵Atherothrombosis Research Centre, University of Ioannina, Ioannina, Greece; ⁹⁶Rigshospitalet, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark; ⁹⁷Departamento Académico Ciclo de Vida, Universidad Autónoma de Guadalajara, Av. Patria 1201, Zapopan 45129, México; ⁹⁸North Estonia Medical Centre, Tallinn University of Technology, Tallinn, Estonia; ⁹⁹Department of Diabetology, LF SZU, Institute of Nutrition, FOAZOS, Coordination Centre for Familial Hyperlipidemias, Slovak Medical University in Bratislava, Bratislava, Slovakia; and ¹⁰⁰Rinku General Medical Centre, Osaka, Japan

Received 5 March 2024; revised 6 August 2024; accepted 31 October 2024

Abstract

Background and Aims Overweight and obesity are modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD) in the general population, but their prevalence in individuals with heterozygous familial hypercholesterolaemia (HeFH) and whether they confer additional risk of ASCVD independent of LDL cholesterol (LDL-C) remains unclear.

Methods Cross-sectional analysis was conducted in 35 540 patients with HeFH across 50 countries, in the EAS FH Studies Collaboration registry. Prevalence of World Health Organization–defined body mass index categories was investigated in adults ($n = 29\,265$) and children/adolescents ($n = 6275$); and their association with prevalent ASCVD.

Results Globally, 52% of adults and 27% of children with HeFH were overweight or obese, with the highest prevalence noted in Northern Africa/Western Asia. A higher overweight/obesity prevalence was found in non-high-income vs. high-income

countries. Median age at familial hypercholesterolaemia diagnosis in adults with obesity was 9 years older than in normal weight adults. Obesity was associated with a more atherogenic lipid profile independent of lipid-lowering medication. Prevalence of coronary artery disease increased progressively across body mass index categories in both children and adults. Compared with normal weight, obesity was associated with higher odds of coronary artery disease in children (odds ratio 9.28, 95% confidence interval 1.77–48.77, adjusted for age, sex, lipids, and lipid-lowering medication) and coronary artery disease and stroke in adults (odds ratio 2.35, 95% confidence interval 2.10–2.63 and odds ratio 1.65, 95% confidence interval 1.27–2.14, respectively), but less consistently with peripheral artery disease. Adjusting for diabetes, hypertension and smoking modestly attenuated the associations.

Conclusions

Overweight and obesity are common in patients with HeFH and contribute to ASCVD risk from childhood, independent of LDL-C and lipid-lowering medication. Sustained body weight management is needed to reduce the risk of ASCVD in HeFH.

Structured Graphical Abstract

Key Question


How common are overweight and obesity in individuals with heterozygous familial hypercholesterolaemia (FH)? Are they associated with atherosclerotic cardiovascular disease independent of lipid-lowering medications and LDL-cholesterol levels?

Key Finding

In this observational study across 50 countries, one in four children and one in two adults with FH was overweight or obese. Obesity was associated with higher odds of coronary artery disease in both adults and children, independent of age, sex, lipid-lowering medications and LDL-cholesterol levels.

Take Home Message

In addition to lipid-lowering medications, sustained weight management is needed from a young age in people with FH to reduce the likelihood of cardiovascular events.



Overweight and obesity are common in patients with heterozygous familial hypercholesterolaemia and are associated with higher LDL cholesterol and greater risk of atherosclerotic cardiovascular disease, independent of lipid-lowering medication. BMI, body mass index; CI, confidence interval; HDL-C, HDL cholesterol; LDL-C, LDL-cholesterol; OR, odds ratio.

Keywords

Dyslipidaemia • Adiposity • Insulin resistance • Atherosclerosis

Introduction

Globally, cardiovascular disease (CVD) affects ~9% of individuals and is responsible for one-third of all deaths and substantial disability.¹ Trends over the last two decades suggest that increased body mass index (BMI)^{2,3} is a key contributor to increasing atherosclerotic CVD (ASCVD) risk worldwide.^{4–6} Atherosclerosis results from the accumulation of apoB-containing lipoproteins (mostly LDL particles)⁷ within the vessel wall, which may be accelerated by the presence of additional risk factors. Atherosclerosis development, even in the general population, often starts from childhood.^{8,9} Familial hypercholesterolaemia (FH) is increasingly recognized as a public health concern^{10–12} with an estimated worldwide prevalence of around 1:300 individuals,^{13,14} and with affected people having increased risk of premature ASCVD. The main driver of this process is the extreme elevation in LDL cholesterol (LDL-C) due to pathogenic variants in the LDL receptor (*LDLR*), apolipoprotein B (*APOB*), or proprotein convertase subtilisin/kexin type 9 (*PCSK9*) genes that impair the receptor-mediated clearance of LDL by the liver. In addition to the lifelong exposure to high LDL-C if untreated or undertreated, people with FH may be exposed to other risk factors known to further increase ASCVD risk,^{15,16} but these have been less thoroughly investigated.

Obesity is a key modifiable cardiovascular risk factor that warrants investigation in people with FH. High BMI was identified in a meta-analysis of three individual studies as one of the risk factors significantly associated with CVD in heterozygous FH (HeFH).¹⁷ However, data were inconsistent, with 'obesity' not reaching statistical significance in relation to ASCVD risk.¹⁷ In the SAFEHEART registry prospective analysis of 2404 patients with HeFH, BMI was associated with increased risk of a combined CVD outcome variable that encompassed myocardial infarction, cardiovascular procedures, stroke, and CVD mortality.¹⁸ While this provided evidence that obesity predicts adverse outcomes in FH, the contribution of obesity to individual conditions, such as coronary artery disease (CAD) or stroke was not dissected. Further, in most world regions, the prevalence of overweight and obesity in people with FH is not known—the size of the population affected with this risk factor may determine the priority of targeting it to reduce ASCVD risk. Specifically, in the present study, we assessed the prevalence of overweight and obesity in patients with HeFH in different world regions. We then investigated whether there is a graded relationship between body weight categories and ASCVD independent of the major risk drivers in FH, namely LDL-C exposure and lipid-lowering medication (LLM), and if present, how early in life does this appear. Using the FH Studies Collaboration (FHSC)^{10,11,19} registry, we attempted to resolve these uncertainties using the largest evidence base to date.

Methods

FHSC registry

The methods of the FHSC project have been described in detail elsewhere.^{10,19} Briefly, the FHSC registry comprises individual-level data supplied by an international consortium of investigators with access to data from patients managed in specialist clinics that serve as national, regional, or local registries of FH. The data from these diverse sources are standardized to a common data dictionary and merged into a single global registry.¹⁹ The structure of the FHSC Coordinating Centre, Steering, and Executive Committees has also been published previously.

The registry includes adults and children with a clinical and/or genetic diagnosis of HeFH or homozygous FH (HoFH). A clinical diagnosis follows established criteria (or modified criteria thereof), such as the Dutch Lipid

Clinic Network (DLCN) criteria, Make Early Diagnoses to Prevent Early Deaths (MEDPED), Simon Broome, Canadian, or Japanese Atherosclerosis Society criteria. The FHSC registry currently consists of >72 000 patients from 73 countries, including 11 953 children and adolescents (aged <18 years).

The protocol and data governance of the registry and its use for research have been approved by the Joint Research Compliance Office and Imperial College Research Ethics Committee (Imperial College London, London, UK). Investigators contributing to the registry provide written confirmation that they comply with their local research and ethical policies and regulations for sharing data with the registry. The FHSC project is registered at ClinicalTrials.gov (NCT04272697).

Present analysis

We conducted a cross-sectional study of adults and children with HeFH using data collected from FHSC registry inception (15 October 2015) till 20 December 2022. Individuals were included if they had a clinical and/or genetic diagnosis of HeFH and had BMI data available at registry entry. In case of adults with a clinical diagnosis, only those with a probable or definite diagnosis of FH (possible and definite in case of Simon Broome criteria) were included. In the case of children, in whom most clinical criteria do not apply, a diagnosis of FH by the treating physician was accepted, and 83% of children had a genetic diagnosis. Patients diagnosed with HoFH were excluded; additionally, participants with a clinical-only diagnosis of HeFH and an untreated LDL-C of 12.9 mmol/L (500 mg/dL) or higher were excluded, as these concentrations make the diagnosis of HoFH likely.

Variables and subgroup definitions

Clinical and laboratory data were supplied by the individual investigators, as measured locally in the respective clinics and laboratories.

Age refers to age at the time of data collection, unless otherwise specified. Adults were defined as those aged 18 years or over at data collection; children and adolescents were those aged 5 to <18 years. The terms 'children' and 'children and adolescents' are used interchangeably throughout the manuscript to refer to the latter group of individuals. Due to greater susceptibility of their body weight to confounders not measured in the present study, children aged <5 years were not included in the study.

Data on BMI were classified into body weight categories defined according to World Health Organization (WHO) cut-offs.^{20,21} In adults, weight categories were: obese (BMI ≥ 30 kg/m²), overweight (BMI 25 to <30 kg/m²), normal weight (BMI 18.5 to <25 kg/m²), and underweight (BMI <18.5 kg/m²).²⁰ Additionally, since Asian populations exhibit CVD risk at lower BMI measurements than Caucasians,²² a sensitivity analysis was conducted where lower cut-offs²² were used for overweight (BMI 23 to <25 kg/m²) and obesity (BMI ≥ 25 kg/m²) for all patients from Asia, while the standard cut-offs²⁰ were retained for all other patients.

For children and adolescents, height, weight, age, and gender data were used to calculate a BMI z-score for each individual using the WHO growth reference data²¹ as implemented in the R statistical package 'anthroplus';²³ the z-scores were then used to define weight categories as follows: obese (BMI z-score > +2SD), overweight (BMI z-score > +1SD and <2SD), normal weight (BMI z-score > -2SD and <+1SD), and underweight (BMI z-score < -2SD).²¹ In cases where only BMI data were provided by the investigators, but not weight or height data, BMI category was defined manually using WHO sex-specific BMI-for-age growth tables.^{24,25}

The atherogenic index, a predictor of CAD, was calculated as log [triglycerides/HDL cholesterol (HDL-C)].^{26,27} Non-HDL-C was calculated as the difference between total cholesterol and HDL-C. Triglyceride-rich lipoprotein-cholesterol (TRL-C; also known as remnant cholesterol) was calculated as total cholesterol: (LDL-C + HDL-C).^{28,29}

Index case was defined as the first documented FH case in a family; non-index cases were defined as relatives with FH identified through screening of the family from the index case.

Atherosclerotic CVD comprised (premature) CAD, peripheral arterial disease (PAD), and stroke. Premature CAD was defined as a CAD diagnosis before the age of 55 years in men and 65 years in women. The countries contributing data on the different types of ASCVD are listed in [Supplementary data online, Table S1](#).

Hypertension was investigator-reported ('no/yes'). Diabetes was coded as no/yes where 'yes' indicated Type 1 diabetes, Type 2 diabetes, or diabetes with type not specified by the investigator. Smoking was coded as 'ever smoker' vs. 'never smoker'.

Geographical regions were defined according to the United Nations (UN) classification.³⁰ Sub-regions were combined to increase statistical power if they included a small number of subjects and were homogeneous with respect to the prevalence of overweight and obesity in the general population and in the current data set. High-income vs. non-high-income countries were defined according to the 2024 World Bank classification of country-income status (defined according to Gross National Income per capita in 2022).³¹ The list of countries included in each UN region or income category is shown in [Supplementary data online, Tables S2–S4](#).

Statistical analysis

All analyses were conducted separately in adults and children/adolescents.

Summary data are presented as median (25th and 75th percentiles) for continuous variables. Categorical variables are reported as absolute numbers (relative frequencies from the total number of participants with data available for the corresponding variable). Group comparisons in [Table 1](#) were performed using Kruskal–Wallis test for continuous variables and Pearson's χ^2 test for categorical variables. To visualize the independent and potential non-linear relationships between BMI and plasma lipids, generalized additive linear models were fitted and plotted, separately for adults and children, with BMI or BMI z-score, respectively, as the independent variable, and the different lipid fractions as outcomes. Smooth terms were modelled using penalized thin-plate regression splines, with knots selected automatically and smoothing parameters optimized via generalized cross-validation as implemented in the R package mgcv.³² These models were adjusted for age, sex, and use of LLM. Skewed lipid variables (HDL-C, total cholesterol, and triglycerides) were log transformed for this analysis.

To assess the heterogeneity in lipid measurements between clusters (countries), we calculated intra-class correlation coefficients (ICCs) using a 2-way random-effects model adjusted for age, sex, and LLM. This quantified the proportion of total variance attributable to differences between countries. Intra-class correlation coefficients were low for lipids not affected by FH, i.e. triglycerides (0.05) and HDL-C (0.07), indicating minimal heterogeneity due to sampling and assay methods across countries. In contrast, higher ICCs were observed for LDL-C (0.28) and total cholesterol (0.27), likely reflecting true differences in the severity of FH-causing genetic variants across countries and regions.

The associations between BMI category and odds of CAD, premature CAD, PAD, or stroke were tested using multivariate logistic regression, using three models, in a complete case analysis. Model 1 was adjusted for age and sex; Model 2 was additionally adjusted for LLM, LDL-C, HDL-C, and triglycerides, and the interaction between LLM and LDL-C; this interaction term was included to account for the LLM effect on LDL-C and capture any effect modification caused by inter-individual variations in the LDL-C response to LLM. Model 3 included all Model 2 covariates, in addition to disease and lifestyle risk factors associated with ASCVD, namely diabetes, hypertension, and smoking. Model 2 was considered the main model because it had the lowest combined risk of over-adjustment and residual confounding. The possibilities of effect modification by age, sex, and index status were tested in this model.

Sensitivity analyses were conducted in the subgroup with a genetic diagnosis of FH. This subgroup comprised 76% ($n = 22\,337$) of the total adult cohort investigated ($n = 29\,265$), and 83% ($n = 5215$) of the children and adolescent cohort ($n = 6275$). Another sensitivity analysis was conducted in adults using lower overweight and obesity cut-offs for patients from Asia, as explained above.

IBM SPSS (Version 28.0; IBM Corp., Armonk, NY, USA) and R software (version 4.2.1 for Windows; R Foundation for Statistical Computing, Vienna, Austria) were used to analyse the data. All statistical tests are two-tailed, and a P -value $<.05$ was considered statistically significant.

Results

Prevalence of overweight and obesity

The study population included 29 265 adults and 6275 children with HeFH and data available on BMI at registry entry. The BMI distribution of the study population, overall and stratified by region and country-income category, is shown in [Figure 1](#). Overall, 36% of adults were overweight, and a further 16% were obese. In children and adolescents, 18% were overweight and 9% were obese. In the genetically confirmed subgroup, the prevalence were as follows: adults: 34% overweight and 14% obese; children: 17% overweight and 7% obese.

In sex-stratified analysis, more men (5727/13 508; 42%) than women (4678/15 750; 30%) were overweight, whereas obesity was more prevalent in women (17%) than men (15%). In children, both overweight and obesity were slightly more prevalent in boys than in girls (see [Supplementary data online, Table S5](#)).

Underweight individuals constituted only 2% of children and 4% of adults ([Figure 1A](#)). There was no significant difference between these individuals and normal weight individuals in the odds of any type of CVD after adjusting for age and sex (see [Supplementary data online, Table S6](#)). Therefore, underweight children and adults were combined with their normal weight counterparts for all subsequent analysis.

There was a higher proportion of adults with overweight or obesity (63%) in non-high-income countries compared with high-income countries (50%; [Figure 1B](#)).

The prevalence of overweight and obesity across the five main UN regions is shown in [Supplementary data online, Figure S1](#). The prevalence of overweight and obesity was lower in Europe than any other world region; data from Africa was limited (adults, $n = 57$) or absent (children). By UN sub-region, the highest prevalence of adults classified as overweight or obese was in the Northern Africa and Western Asia region (82% with overweight or obesity), and the lowest was in Western Europe ([Figure 1C](#)). Among children the lowest proportion considered to be overweight or obese (approximately one in five children) was also found in Western Europe ([Figure 1C](#)).

Population characteristics by weight status

Subject characteristics by BMI category are summarized in [Table 1](#). Adults with HeFH who were classifiable as obese were diagnosed with HeFH 9 years later than those with normal weight (median age at FH diagnosis 49 vs. 40 years; $P < .001$). The late FH diagnosis in adults with obesity did not appear to be driven by systematic differences in the prevalence of obesity and FH detection methods across countries, since it was apparent in most UN sub-regions in stratified analysis (see [Supplementary data online, Table S7](#)). Conversely, in children, age at FH diagnosis was nearly a year younger in those with obesity vs. normal weight ([Table 1](#)). In the genetically confirmed group, similar findings were observed: age at FH diagnosis in adults in the normal weight, overweight, and obese categories, respectively, was [median (25th, 75th percentiles)] 39.0 (27.7, 52.3), 47.2 (36.0, 59.5), and 48.7 (37.5, 59.2) years. Equivalent values for genetically diagnosed children were: 11.1 (8.0, 14.5), 10.6 (8.0, 13.6), and 9.9 (7.2, 12.9) years.

Table 1 Characteristics of the study population by age group and body weight status^a

Variable	Children and adolescents				Adults				P-value
	n	Normal weight n = 4608 ^b	Overweight n = 1118	Obese n = 549	n	Normal weight n = 14 045 ^c	Overweight n = 10 404	Obese n = 4796	
Age, years	6275	11.0 (8.0, 14.4) ^b	10.8 (8.0, 13.9)	10.0 (7.9, 12.9)	29 245	42 (30, 55)	50 (39, 61)	52 (41, 61)	<.001
Sex, n (%)	6275				29 237				<.001
Male		2225 (48%)	564 (50%)	323 (59%)		5689 (41%)	5724 (55%)	2083 (43%)	
Female		2383 (52%)	554 (50%)	226 (41%)		8351 (59%)	4678 (45%)	2712 (57%)	
Age at FH diagnosis, years	6205	10.8 (7.8, 14.2)	10.2 (7.7, 13.0)	10.0 (7.4, 12.0)	26 104	40 (28, 53)	48 (37, 59)	49 (38, 58)	<.001
Index case, n (%)	5976	990 (22%)	358 (34%)	243 (48%)	21 900	2317 (21%)	2390 (31%)	1286 (40%)	<.001
Lipid-lowering medication, n (%)	6170	1463 (32%)	336 (31%)	134 (25%)	28 213	8382 (62%)	7245 (72%)	3490 (76%)	<.001
Statins, n (% ^d)		304 (21%)	108 (32%)	53 (40%)		6489 (77%)	6254 (86%)	3109 (89%)	<.001
Smoking, n (%)	4849	175 (4.7%)	52 (6.5%)	20 (5.9%)	27 609	5015 (37.8%)	3908 (39.8%)	1827 (40.5%)	<.001
Hypertension, n (%)	5189	5 (0.1%)	4 (0.5%)	7 (1.9%)	26 858	1584 (12%)	2534 (27%)	1826 (41%)	<.001
Diabetes, n (%)	4988	11 (0.3%)	3 (0.4%)	2 (0.6%)	26 744	365 (2.8%)	606 (6.4%)	679 (15%)	<.001
Premature coronary artery disease, n (%)					25 083	808 (6.5%)	1251 (14%)	808 (21%)	<.001
Coronary artery disease, n (%)	6172	3 (<0.1%)	2 (0.2%)	4 (0.7%)	25 720	1381 (11%)	2054 (22%)	1262 (30%)	<.001
Stroke, n (%)	4780	0 (0%)	0 (0%)	1 (0.3%)	23 522	186 (1.6%)	233 (2.8%)	134 (3.7%)	<.001
Peripheral artery disease, n (%)	823	0 (0%)	0 (0%)	0 (0%)	8836	133 (3.8%)	181 (5.4%)	144 (7.4%)	<.001
United Nations Region	6275				29 245				<.001
Africa		0 (0.0%)	0 (0.0%)	0 (0.0%)		7 (0.0%)	25 (0.2%)	25 (0.5%)	
Americas		186 (4.0%)	56 (5.0%)	50 (9.1%)		996 (7.1%)	857 (8.2%)	457 (9.5%)	
Asia		36 (0.8%)	12 (1.1%)	5 (0.9%)		1050 (7.5%)	962 (9.2%)	580 (12.1%)	
Europe		4353 (94.5%)	1038 (92.8%)	487 (88.7%)		11 914 (84.8%)	8484 (81.5%)	3673 (76.5%)	
Oceania		33 (0.7%)	12 (1.10%)	7 (1.3%)		84 (0.6%)	88 (0.8%)	64 (1.3%)	

^aStudy population with age data available. Data are median (25th, 75th percentiles) or n (% of total population, unless otherwise indicated). P-values, in italics, are from Kruskal–Wallis test for continuous variables or Pearson's χ^2 test for categorical variables.

^bn = 222 underweight children/adolescents.

^cn = 574 underweight adults.

^dPercent of those on lipid-lowering medication.




Figure 1 Prevalence of underweight, normal weight, overweight, and obesity in people with heterozygous familial hypercholesterolaemia pooled globally (A), by country-income category (B), and by United Nations sub-regions (C). Adults were aged 18 years or older; children and adolescents were aged 5 to <18 years. Body mass index categories were defined by World Health Organization body mass index cut-offs (see Methods section for details). In B and C, underweight individuals are pooled with the normal weight category; data are sorted in descending order of combined overweight and obesity prevalence. No formal statistical comparisons are conducted as these prevalence are for descriptive purposes only. ¹n = 5 adults from Nigeria were not included in this analysis

In both children and adults, the proportion of patients who were index cases of HeFH increased across BMI categories; for example, 22% of normal weight children were index cases, compared with 48% of children with obesity ($P < .001$). Hypertension, diabetes, and CVD were more frequent in overweight than normal weight individuals, and even more frequent in individuals with obesity, with the exception of diabetes in children (Table 1).

Approximately two-thirds of children and one-third of adults were not receiving LLM at registry entry. Overall, LDL-C, non-HDL-C, TRL-C, triglycerides, and the atherogenic index were higher across higher BMI categories in both children and adults, and HDL-C was lower, irrespective of use of LLM (Table 2). The differences in total cholesterol and LDL-C across weight categories were generally less marked among patients who were receiving LLM than those who were

Table 2 Plasma lipid concentrations across body mass index categories by age group and lipid-lowering medication status^a

	Not receiving lipid-lowering medication				Receiving lipid-lowering medication				
	<i>n</i>	Normal weight <i>n</i> = 3080	Overweight <i>n</i> = 759	Obese <i>n</i> = 398	<i>n</i>	Normal weight <i>n</i> = 1463	Overweight <i>n</i> = 336	Obese <i>n</i> = 134	P-value
Total cholesterol, mmol/L	3428	6.30 (5.40, 7.27)	6.50 (5.62, 7.50)	6.70 (5.84, 7.80)	1818	5.82 (4.97, 6.95)	6.00 (5.09, 6.86)	6.05 (5.19, 7.10)	.34
LDL cholesterol, mmol/L	3297	4.57 (3.70, 5.51)	4.76 (3.92, 5.74)	4.90 (3.99, 6.09)	1792	4.19 (3.36, 5.20)	4.38 (3.46, 5.17)	4.39 (3.53, 5.35)	.51
HDL cholesterol, mmol/L	3398	1.30 (1.06, 1.52)	1.27 (1.07, 1.50)	1.27 (1.03, 1.50)	1806	1.21 (1.01, 1.42)	1.14 (0.96, 1.40)	1.12 (0.91, 1.32)	<.001
Triglycerides, mmol/L	2507	2.02 (1.40, 2.82)	2.22 (1.63, 3.32)	2.52 (1.83, 3.70)	1760	1.91 (1.37, 2.68)	2.07 (1.53, 2.90)	2.51 (1.68, 3.71)	<.001
TRL cholesterol, mmol/L	3180	0.40 (0.30, 0.57)	0.44 (0.31, 0.64)	0.49 (0.34, 0.78)	1761	0.39 (0.27, 0.54)	0.41 (0.30, 0.60)	0.50 (0.32, 0.76)	<.001
Non-HDL cholesterol, mmol/L	959	5.30 (4.50, 6.34)	5.61 (4.64, 6.70)	5.90 (4.97, 6.87)	383	4.97 (3.83, 6.10)	5.00 (3.84, 5.89)	4.81 (4.25, 6.40)	.8
Atherogenic index	2492	0.48 (0.08, 0.93)	0.62 (0.26, 1.10)	0.74 (0.32, 1.25)	1757	0.46 (0.09, 0.90)	0.56 (0.22, 0.99)	0.83 (0.37, 1.22)	<.001
Adults	<i>n</i>	<i>n</i> = 5246	<i>n</i> = 2764	<i>n</i> = 1086	<i>n</i>	<i>n</i> = 8382	<i>n</i> = 7245	<i>n</i> = 3490	P-value
Total cholesterol, mmol/L	5902	7.11 (5.93, 8.46)	7.70 (6.50, 9.10)	7.89 (6.65, 9.20)	16720	5.95 (5.00, 7.49)	6.04 (4.99, 7.73)	6.26 (5.08, 8.03)	<.001
LDL cholesterol, mmol/L	5779	5.16 (4.10, 6.41)	5.60 (4.63, 6.85)	5.76 (4.69, 6.98)	16423	4.05 (3.11, 5.38)	4.09 (3.10, 5.48)	4.29 (3.19, 5.87)	<.001
HDL cholesterol, mmol/L	5723	1.32 (1.07, 1.61)	1.22 (0.99, 1.50)	1.19 (0.99, 1.47)	16280	1.33 (1.09, 1.60)	1.20 (0.98, 1.47)	1.14 (0.95, 1.38)	<.001
Triglycerides, mmol/L	4761	2.51 (1.73, 3.64)	3.44 (2.41, 4.91)	4.12 (2.83, 5.94)	15392	2.31 (1.65, 3.39)	3.10 (2.18, 4.54)	3.71 (2.56, 5.25)	<.001
TRL cholesterol, mmol/L	5573	0.50 (0.34, 0.73)	0.69 (0.48, 0.98)	0.80 (0.54, 1.16)	15775	0.47 (0.32, 0.70)	0.60 (0.41, 0.91)	0.70 (0.49, 1.01)	<.001
Non-HDL cholesterol, mmol/L	5713	5.71 (4.57, 6.98)	6.37 (5.26, 7.70)	6.62 (5.38, 7.88)	16251	4.55 (3.58, 6.05)	4.71 (3.66, 6.28)	4.94 (3.81, 6.68)	<.001
Atherogenic index	4707	0.63 (0.19, 1.10)	1.05 (0.57, 1.51)	1.25 (0.74, 1.69)	15253	0.55 (0.14, 1.02)	0.94 (0.49, 1.43)	1.17 (0.70, 1.64)	<.001

^aData are median (25th, 75th percentiles). P-values, in italics, are from Kruskal-Wallis test.




Figure 2 A-G: Estimated means and 95% confidence intervals of different lipid fractions by body mass index z-score (in children and adolescents aged 5 to <18 years; left panels) and body mass index in adults (aged ≥ 18 years; right panels) with adjustment for age, sex, and use of lipid-lowering medication. The vertical lines (green, yellow, and red) mark the beginning of the normal weight, overweight, and obese BMI ranges, respectively. The lowest and highest 1% of the independent variable are not shown. Note the different scales on the y-axes for children and adults. BMI, body mass index; TRL-C, triglyceride-rich lipoprotein cholesterol

untreated, and, among children receiving LLM, there was no significant difference in total cholesterol or LDL-C or by weight category classes (Table 2).

Association between body mass index and lipid levels

In generalized additive linear models adjusted for age, sex, and LLM, BMI in adults and BMI z-score in children were positively associated with total cholesterol, LDL-C, non-HDL-C, and triglycerides (all $P < .001$) and inversely associated with HDL-C (Figure 2). In adults, the plots showed stronger associations across the normal weight range, with attenuation of the association in the obese BMI range. In contrast, among children, there was no attenuation of the association at higher BMI.

An increase in BMI from the start of the normal weight range (18.5 kg/m²) to the BMI cut-off for obesity (30 kg/m²) was associated with an ~ 0.5 mmol/L higher LDL-C, 1.8 mmol/L higher triglycerides, and 0.2 mmol/L lower HDL-C in adults, after controlling for age, sex, and LLM. The equivalent differences in children were: LDL-C, 0.3 mmol/L; triglycerides, 0.6 mmol/L; and HDL-C, 0.07 mmol/L, respectively. A higher BMI in adults and children was also positively associated with TRL-C and the atherogenic index (both $P < .001$; Figure 2). Essentially similar associations to those in the total cohort were observed in the cohort with genetically confirmed HeFH (all $P < .001$; Supplementary data online, Figure S2).

Associations of overweight and obesity with atherosclerotic cardiovascular disease

Coronary artery disease was present in 0.7% of children with obesity, 0.2% of children with overweight, and 0.07% of normal weight children (total n with CAD = 9; $P < .001$; Table 1). Obesity was associated with significantly higher odds of CAD in children, but the confidence intervals (CIs) were wide due to the small number of events. The odds ratio (OR) in children with obesity vs. normal weight, adjusted for age and sex (Model 1) was 12.29 (95% CI: 2.96–51.03; $P < .001$). After adjustment for lipids and use of LLM (Model 2), the OR was 9.28 (95% CI 1.77–48.77; $P = .008$). None of the children had PAD at registry entry. One child had a history of stroke and a BMI in the obese range (Table 1).

Adults with obesity had three times higher prevalence of CAD than normal weight adults (30% vs. 11%; Table 1). The prevalence of stroke and PAD in adults was low overall, but it was twice as high among those with obesity (3.7% and 7.4%, respectively) than in those with normal weight (1.6% and 3.8%). Being overweight or obese, vs. having normal weight, was associated with ~ 1.5 -fold and 2.3-fold higher odds of having CAD or premature CAD (all, $P < .001$; Model 2; Figure 3A and B). Further adjustment for age at FH diagnosis or index case status did not alter the results (data not shown). Odds ratios for stroke and PAD were also higher among adults with overweight and obesity vs. normal weight, but the magnitude of the associations was lower than that for CAD (Figure 3C and D). With further adjustment for diabetes, hypertension, and smoking (Model 3), all associations were attenuated, but were still statistically significant for CAD and premature CAD, borderline significant for stroke, and no longer significant for PAD (Figure 3). In sensitivity analysis using lower overweight and obesity




Figure 3 A-D: Odds ratios and 95% confidence intervals for the presence of different types of cardiovascular disease in adults with heterozygous familial hypercholesterolaemia at registry entry by body mass index category. Models are adjusted for the following variables: Model 1, age and sex; Model 2, age, sex, lipid-lowering medication, LDL cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol \times lipid-lowering medication interaction; Model 3, all Model 2 variables, plus diabetes, hypertension, and smoking. Body mass index categories were defined by World Health Organization body mass index cut-offs (see Methods section for details)

cut-offs for patients from Asian countries, findings were similar to or stronger than in the primary analysis (see [Supplementary data online, Table S8](#)).

In the subgroup with genetically confirmed FH, essentially similar significant associations of overweight and obesity with CAD, premature CAD, and stroke were observed as those in the total population, but those with PAD were weaker and not statistically significant (see [Supplementary data online, Table S9](#)).

[Supplementary data online, Table S10](#) shows the odds of ASCVD by BMI category in different adult subgroups in the total population. No evidence of effect modification by sex was noted for any ASCVD outcome, but the association of BMI category with CAD appeared stronger in younger vs. older adults (P -interaction $< .001$), and that of BMI category with PAD tended to be stronger in non-index vs. index cases (P -interaction = .060).

Discussion

Among 35 540 individuals with HeFH, approximately half of adults and a quarter of children were found to be overweight or obese. This was more marked in regions of the world where in the general population obesity is more prevalent than other regions. Among both adults and children with HeFH, overweight and obesity were associated with a more atherogenic lipid profile and with higher odds of ASCVD, independent of age, sex, lipid profile, and use of LLM ([Structured Graphical Abstract](#)). In adults, obesity was associated with FH being diagnosed almost a decade later than in those with normal weight. Given the late age of diagnosis of FH globally (average 44 years),¹⁰ and the higher prevalence of FH in some regions of the world where obesity is also common, the present findings highlight the importance of a global risk factor management approach including addressing lifestyle factors in those with FH, as recommended in most guidelines.³³

The high prevalence of overweight and obesity found in the present study should be viewed in the context of the population prevalence of these conditions worldwide.³⁴ Globally, obesity prevalence in the general adult population in 2016 was estimated at 13% of men and 15% of women³⁴; in children, the prevalence was 5.6% of girls and 7.8% of boys.³⁴ Bearing in mind the methodological differences across studies, the prevalence of obesity among adults (16%) and children (9%) appears similar to the general population. In the general population, compared with normal weight adults, people with overweight and obesity, respectively, have a 20% and 60% higher risk of CAD.⁴ Stroke and PAD in the general population are also linked to weight in a graded fashion, with those with obesity having the highest risk.⁵ In patients with HeFH, we observed two times higher odds of CAD and 60%–80% higher odds of stroke and PAD in adults with obesity compared with normal weight adults, independent of age, sex, lipids, and LLM. In adults, the increase of LDL-C with greater BMI was in fact attenuated at the highest BMI; this is in line with findings in the general population,³⁵ possibly resulting from reduced intestinal cholesterol absorption in severe obesity,³⁶ which may partly explain why the obesity–ASCVD association was independent of LDL-C.

We tested whether diabetes, hypertension, and smoking explained some of the associations of obesity with ASCVD. Adjusting for these factors weakened the associations, but a substantial independent contribution of obesity remained for CAD and stroke. This is consistent with findings in 1.8 million people from the general population that treating hypertension, diabetes, and hyperlipidaemia only mitigates half the excess risk of CAD and three quarters of the excess risk of stroke associated with high BMI.³⁷ The residual risk might be explained by other factors not evaluated in the present study, including endothelial dysfunction, thrombogenesis, and inflammation.³⁸ While infiltration of apolipoprotein B-containing lipoproteins, most notably LDL-C, in the artery wall is a critical event initiating atherosclerosis, it is the subsequent recruitment of monocytes and development of foam cells,

inflammation and endothelial activation, that culminate in forming an atherosclerotic plaque in the vessel wall.³⁹ If the fibrous cap of the plaque ruptures, it facilitates thrombogenesis, leading to ischaemic events. At all these pathophysiologic stages, obesity and the associated insulin resistance contribute to phenotypes that accelerate atherothrombosis, including increased apolipoprotein B-containing lipids, systemic inflammation, and hypercoagulability.⁴⁰ Crucially, in the general population, intentional weight loss ameliorates these processes⁴¹ and reduces CVD events.^{42,43} Our findings that the pattern of association of obesity with ASCVD in patients with FH parallels that in the general population suggests that patients with FH stand to equally benefit from maintaining a healthy weight with regards to ASCVD, on top of their benefit from pharmacologic LDL-C reduction.

Atherosclerosis begins in childhood, with obesity accelerating the process through insulin resistance, which may directly affect the vessel wall or contribute to atherogenic dyslipidaemia, such as lower HDL-C and higher remnant cholesterol in triglyceride-rich lipoproteins.⁴⁴ In the general paediatric population, obesity has been linked to endothelial dysfunction and inflammation, starting as early as age 8,^{45,46} and to a higher risk of stroke before age 50,⁴⁷ but ASCVD events in childhood are rare. In children with HeFH, where atherosclerosis is accelerated due to high LDL-C from birth, clinical ASCVD also remains uncommon. Our recent analysis of over 11 000 children and adolescents with HeFH, the largest such data set to date, revealed a CAD prevalence of 0.3% and a stroke prevalence of <0.1%.⁴⁸ In the present study of those with BMI data, the occurrence of CAD was 10 times higher in children with obesity (0.7%) vs. those with normal weight (0.07%). Due to the small total number of events these results should be interpreted with caution, but the higher occurrence of CAD in children with obesity was consistent with the higher levels of atherogenic lipids observed in this group. Childhood, therefore, comprises a window of opportunity not only for FH detection and treatment to reduce lifetime LDL-C exposure, but also for management of traditional ASCVD risk factors, including obesity, to decrease ASCVD events.^{8,49}

To our knowledge, this is the first study to systematically investigate the prevalence of obesity and its contribution to ASCVD in children and adults with HeFH globally using individual-level data, but there have been relevant reports from individual countries. In the Dutch HeFH registry cohort, higher BMI was associated with a higher OR for CAD independent of LDL-C, but it was not clear whether it was also independent of LLM intake.⁵⁰ In another study of 2400 Dutch patients, those who developed CVD had higher mean BMI.⁵¹ In an early study of 120 Canadian men with FH, high waist circumference and hyperinsulinaemia markedly increased the odds of CAD, independent of LDL-C.⁵² The present study consolidates and extends these findings using clinically relevant body weight categories, showing that obesity and overweight are common in FH, and increase the likelihood of both CAD and stroke across the life-course starting in childhood, regardless of LDL-C and LLM intake.

Screening for FH is not systematically performed in most healthcare systems; hence, it is often the clinical phenotype that triggers investigations for FH. Consistent with this, people with obesity in the present study were more likely to be index cases, i.e. the first case of FH discovered in a family. Our data show an interesting distinction between adults and children which warrants discussion. Children with obesity were on average, nearly 1 year younger at FH diagnosis than normal weight children, but adults with obesity were 9 years older at FH diagnosis. These could be explained by biases in detection due to health perception. Children are not expected to be obese, and this is considered unhealthy and leads to investigations, hence, FH detection at a

slightly younger age in children with obesity. In contrast, there may be a propensity in adult healthcare to attribute hyperlipidaemia and/or ASCVD to the obese state, rather than consider an FH diagnosis. Thus, obesity may confer a disadvantage later in life regarding FH detection. Additionally, obesity could delay a diagnosis of FH by making it more challenging to distinguish from phenotypically similar conditions such as mixed dyslipidaemia resulting from insulin resistance. Further, a mixed dyslipidaemia phenotype may result in some individuals being considered to have familial combined hyperlipidaemia⁵³ rather than FH and obesity. In our analyses of genotypically confirmed FH, the same associations were observed.

Strengths and limitations

The present study provides the most reliable evidence to date of the prevalence of obesity and its association with ASCVD in individuals with HeFH, drawn from 50 countries across 6 continents. This allowed some comparison of obesity prevalence across geographical regions and World Bank income groups; however, there was an over-representation of Europe and high-income countries. Additional strengths include comparison of the child and adult populations, providing insights for public health strategies from childhood. However, the data are cross-sectional, and while a large body of evidence in the general population links obesity to ASCVD causation, reverse causality cannot be excluded. Further, despite the value of BMI in categorizing overweight and obesity, its limitations in not distinguishing adiposity or body fat distribution are well recognized. It was not possible to assess the association of central obesity with ASCVD due to the absence of data on waist-hip ratio in most patients, so this warrants investigation in future studies. To account for the fact that populations of different ethnicities have different body fat% or cardio-metabolic risk at the same BMI,²² we analysed our data using the global WHO cut-offs for overweight/obesity, as well as using lower cut-offs for Asian patients, and the associations of weight with ASCVD were similar. Thus, although the proportion of Caucasian patients was higher than other ethnicities in the present study, we believe our findings regarding the association of obesity with ASCVD are generalizable to all patients with FH globally. On the other hand, the prevalence of overweight and obesity in world regions, sub-regions or country-income groups with a relatively small number of patients (e.g. Oceania, various Asia sub-regions, and non-high-income countries especially children's data) should be interpreted with caution and require investigating in larger data sets. It is possible that some patients with a clinical FH diagnosis were not true FH patients; however, in sensitivity analyses using only those with a genetically confirmed diagnosis, the relationship between weight and odds of ASCVD was still present. Finally, we adjusted for potential confounders in the obesity-ASCVD associations, but there may have been residual confounding from unmeasured variables, such as diet, physical activity and socio-economic state.

Conclusions

The data from 6275 children and 29 265 adults provide evidence that obesity is common in those with HeFH and is associated with a more severe hyperlipidaemia phenotype and greater likelihood of ASCVD from childhood. Given their already augmented risk of ASCVD, patients with FH should be prioritized from the point of FH diagnosis for intensive lifestyle management aimed at maintaining a healthy weight, to

reduce their lifetime risk of CVD events. A holistic approach, integrating body weight management with LDL-C-lowering treatments, should be used to improve cardiovascular outcomes in people with FH.

Acknowledgements

K.I.D. acknowledges support for a PhD Studentship from the National Institute for Health and Care Research (NIHR) Applied Research Collaboration Northwest London. K.K.R. acknowledges support from the NIHR Applied Research Collaboration Northwest London and Imperial NIHR Biomedical Research Centre. The views expressed in this Article are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. A.J.V.-V. acknowledges support from the Programme “Beatriz Galindo” from the Ministry of Universities, Spain, and University of Seville, Spain. A.L.C. is supported in part by the grant *Ricerca Corrente* from the Ministry of Health to IRCCS MultiMedica. H.N. acknowledges support from the Ministry of Higher Education (MOHE), National Professorial Council (MPN) and Universiti Teknologi MARA (UiTM), Malaysia.

Supplementary data

Supplementary data are available at *European Heart Journal* online.

Declarations

Disclosure of Interest

A.E. reports participation in research grants to Imperial College London from Amgen, Daiichi Sankyo, and Regeneron, during the conduct of the study. A.J.V.-V. reports participation in research grants to Imperial College London from Pfizer, Amgen, Merck Sharp & Dohme, sanofi-aventis, Daiichi Sankyo, and Regeneron, during the conduct of the study; personal fees for consulting from Bayer and Regeneron and honoraria for lectures from Amgen, Mylan, Akcea, and Ferrer, outside the submitted work. F.B. reports honoraria from Amgen, Novartis, Novo Nordisk, and Viatri, outside the submitted work. A.R.M.L. reports grants from Pfizer, Amgen, MSD, sanofi-aventis, Daiichi Sankyo Enterprise, and Regeneron, during the conduct of the study. C.A.T.S. reports grants from Pfizer, Amgen, Merck Sharp & Dohme, sanofi-aventis, Daiichi Sankyo, and Regeneron, during the conduct of the study. K.I.D. reports grants from Pfizer, Amgen, Merck Sharp & Dohme, sanofi-aventis, Daiichi Sankyo, and Regeneron to the host institution, during the conduct of the study; and personal fees from Bayer and Regeneron, outside the submitted work. A.L.C. received research funding and/or honoraria for advisory boards, consultancy or speaker bureau from Amarin, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceutical, Medscape, Menarini, Merck, Novartis, Peer Voice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus, Ultragenyx, and Viatri. T.F. reports honoraria from Sanofi and Novartis, outside the submitted work. T.F. was supported by the project National Institute for Research of Metabolic and Cardiovascular Diseases, programme EXCELES (ID project no. LX22NPO5104) and funded by the European Union—Next Generation EU. G.K.H. reports that until 2019 he has received institutional support and/or consulting fees from Amgen, Aegerion, AstraZeneca Eli Lilly, Genzyme, Ionis, Kowa, Novartis, Novo Nordisk, Pfizer, Kowa, Regeneron, Sanofi, Roche, and the Medicines Company; he also received a grant for funding of a PhD salary from Klinkerpad fonds, part-time employee of Novo Nordisk AS, and is a shareholder

of Novo Nordisk. F.J.R. has received research grants, honoraria, or consulting fees for professional input and/or delivered lectures from Sanofi, Regeneron, Amgen, Novartis, and LIB Therapeutics outside the submitted work. P.M. reports grants from Amgen and Sanofi, from null, outside the submitted work; HS IIS grants from Akcea, Pfizer, MSD, AMGEN, Genzyme-Sanofi, Synageva, Amryt, Synageva, and Alexion; consulting from Amgen, Akcea, Synageva, NAPP, Novartis, Takeda, Sanofi, Pfizer, and Kowa; and honoraria Amgen, Akcea, Synageva, NAPP, IONIS, Novartis, Takeda, Sanofi, Pfizer, and Kowa, all outside of the submitted work. R.D.S. reports personal fees from Amryt, AstraZeneca, Aché, Abbott, Biolab, Esperion, Hypera, Getz Pharma, Kowa, EMS, Pfizer, Novo Nordisk, Merck, grants and personal fees from Amgen, PTC Therapeutics, Novartis, personal fees from Sanofi, outside the submitted work. H.S. reports honoraria from AstraZeneca, Bayer Vital, MSD Sharp & Dohme, Novartis, Servier, sanofi-aventis, Boehringer Ingelheim, Daiichi Sankyo, Amgen, and Pfizer, and consulting fees from AstraZeneca, Amgen, MSD Sharp & Dohme, outside of the submitted work. G.F.W. reports grants and personal fees from Amgen, Sanofi, Esperion, CRISPR Therapeutics, grants and personal fees from Arrowhead and Novartis, outside the submitted work. M.Arca. received lecture fees and travel grant from Amryt unrelated to the current study. K.A.-R. reports personal fees from Sanofi and Abbott, outside the submitted work. F.A. reports personal fees from AMGEN, AMRYT Pharma, and NOVARTIS, outside the submitted work. M.A. received research grant support and lecturing fees from Alfasigma, Amgen, Amryt, Daiichi Sankyo, Ionis/Akcea, Novartis, Pfizer, Regeneron, Sanofi, Sobi, Viatri, and Ultragenyx. M.A. received honoraria for lecturing and consulting from Akcea, Amarin, Amgen, Amryt, Daiichi, Genzyme, Menarini, Novartis, Piam, Sanofi, Takeda, and Sobi. M.Banach. reports speakers' bureau and/or consultant fees from Adamed, Amgen, Daiichi Sankyo, Ionis, KRKA, New Amsterdam, Merck, Novartis, Novo Nordisk, Pfizer, Polpharma, Novartis, Sanofi, Teva, and Zentiva; and grants from Amgen, Daiichi Sankyo, Mylan/Viatri, Novartis, Sanofi, outside the submitted work. M.B. reports personal fees from Amgen, KRKA, Polpharma, Novartis, New Amsterdam, sanofi-aventis, Teva, Zentiva, Amgen, Daiichi Sankyo, Esperion, Novartis, Novo Nordisk, Polfarmex, and sanofi-aventis, grants from Amgen, Daiichi Sankyo, Mylan/Viatri, Sanofi and Valeant; outside the submitted work. C.J.B. reports grants from FH Registry of the Austrian Atherosclerosis Society, during the conduct of the study; personal fees from AMGEN, NOVARTIS, DAIICH_SANKYO, and SOBI, from null, outside the submitted work. M.B. reports grants from Alexion, outside of the submitted work. L.R.B. reports honoraria from Amgen, HLS Therapeutics, Novartis, Novo Nordisk, Pfizer, and Ultragenyx. K.C. reports honoraria for lectures from Amgen, Sanofi, Novartis, Polpharma, and is grateful for a unrestricted grant from the Polish Ministry of Health and Sanofi. P.C. reports honoraria from Amgen and Novartis. D.C. reports consulting fees from Ultragenyx, Organon, and Novartis. O.S.D. reports grants and personal fees from SANOFI, AMGEN, and Daiichi Sankyo, personal fees from VIATRIS and NOVARTIS, outside the submitted work. U.G. reports honoraria for lectures from Novartis and AstraZeneca, outside the submitted work. M.H.-S. reports stock holding of Liid Pharmaceuticals, honoraria from MEDPACE, Amgen, Kowa, Ascent Development, MSD and Bayer, outside the submitted work. S.E.H. is the medical director of Storegene, a UCL spin-off company which offers genetic testing for FH and he reports consulting fees from Verve Therapeutics. W.K. reports honoraria from Amgen, Novartis, Meiji, Kowa, Boehringer Ingelheim, and Novo Nordisk, outside the submitted work. G.L. has given talks, attended conferences, received consultancy fees from Abbott Laboratories,

Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Grindex, KRKA, MSD, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier Laboratories, Siemens Laboratories, and Zentiva. U.L. reports participation in research grants to Leipzig University from Amgen, Daiichi Sankyo, and Novartis, as well as honoraria from Amgen, Daiichi Sankyo, Novartis, and Sanofi, all outside the submitted work. E.L. reports personal fees and non-financial support from Amgen, personal fees from Servier, Boehringer Ingelheim, MSD, Lilly, Novartis, and Chiesi, and personal fees and non-financial support from AstraZeneca and Bayer, outside the submitted work. V.M. reports supervising a participant site in a clinical trial for the Select study (Novo Nordisk), and being on the Advisory board for Amarin and Daiichi Sankyo. W.M. reports grants and personal fees from Amgen and Sanofi, during the conduct of the study; grants and personal fees from Amryt Pharmaceuticals, Abbott Diagnostics, Akcea Therapeutics, SOBI, personal fees from Novartis Pharma GmbH and Vifor Pharma, other from SYNLAB Holding Deutschland GmbH, outside the submitted work. A.R.M. reports personal fees from Sanofi and CEO of Diagen Research Institute outside of the submitted work. H.N. reports participation in a community research grant from Amgen, outside the submitted work. B.G.N. reports consultancies/talks sponsored by AstraZeneca, Sanofi, Regeneron, Akcea, Amgen, Kowa, Denka, Amarin, Novartis, Novo Nordisk, Esperion, Silence Therapeutics, Ultragenyx, Mankind, USV, and Lilly, outside the submitted work. A.G.P. reports honoraria for lectures from Amgen, AstraZeneca, Novartis, Novo Nordisk, and Servier outside the submitted work. H.S. reports honoraria from AstraZeneca, Bayer Vital, MSD Sharp & Dohme, Novartis, Servier, sanofi-aventis, Boehringer Ingelheim, Daiichi Sankyo, Amgen, and Pfizer, and consulting fees from AstraZeneca, Amgen, MSD Sharp & Dohme, outside of the submitted work. A.B.S. reports honoraria for lectures from Novartis, Servier, Menarini, and Abbott. E.S. reports personal fees from Amgen, Sanofi, Novartis, Merck, Esperion, and AstraZeneca, and grants from Ionis, grants from Novo Nordisk, outside the submitted work. B.V. reports honoraria from Amgen, Sanofi, Novartis, Novo Nordisk, Zentiva, and Viatrix, outside the submitted work. S.Y. reports personal fees from Kowa Company, Otsuka Company, Novartis, Skylight Biotech, and Hayashibara Co., outside the submitted work. K.K.R. reports grants from Amgen, Daiichi Sankyo, Regeneron, Sanofi, Pfizer, and MSD, during the conduct of the study; grants and personal fees from Sanofi, and personal fees from Amgen, Regeneron, Pfizer, Viatrix, Abbott, AstraZeneca, Lilly, Kowa, Novo Nordisk, Boehringer Ingelheim, Esperion, Cargene, Resverlogix, Novartis, Silence Therapeutics, New Amsterdam, SCRIBE Therapeutics, CRISPR, VAXXINITY, AMARIN, CSL Behring, Bayer, Beren Therapeutics, and Biologix Pharma, outside the submitted work. All other authors have nothing to declare.

Data Availability

The data are not available for public sharing, due to the restrictions of the FHSC Data Sharing Agreements.

Funding

The EAS FHSC is an academic initiative that has received funding from a Pfizer Independent Grant for Learning & Change 2014 (16157823) and from investigator-initiated research grants to Imperial College London from Amgen, Merck Sharp & Dohme, Sanofi-Aventis, Daiichi Sankyo, and Regeneron. K.I.D. acknowledges support for a PhD Studentship from the National Institute for Health and Care Research (NIHR) Applied Research Collaboration Northwest London. K.K.R.

acknowledges support from the NIHR Applied Research Collaboration Northwest London and Imperial NIHR Biomedical Research Centre. The views expressed in this Article are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. A.J.V.-V. acknowledges support from the Programme “Beatriz Galindo” from the Ministry of Universities, Spain, and University of Seville, Spain. A.L.C. is supported in part by the grant Ricerca Corrente from the Ministry of Health to IRCCS MultiMedica. H.N. acknowledges support from the Ministry of Higher Education (MOHE), National Professorial Council (MPN) and Universiti Teknologi MARA (UiTM), Malaysia. The Austrian Familial Hypercholesterolemia Registry, which contributed to the FHSC registry, has been supported by funds from the Austrian Heart Foundation and the Tyrolean Regional Government.

Ethical Approval

The protocol and data governance of the registry and its use for research have been approved by the Joint Research Compliance Office and Imperial College Research Ethics Committee (Imperial College London, London, UK). Investigators contributing to the registry provide written confirmation that they comply with their local research and ethical policies and regulations for sharing data with the registry.

Pre-registered Clinical Trial Number

The FHSC project is registered at ClinicalTrials.gov (NCT04272697).

References

- Mensah GA, Fuster V, Murray CJL, Roth GA. Global burden of cardiovascular diseases and risks, 1990–2022. *J Am Coll Cardiol* 2023;**82**:2350–473. <https://doi.org/10.1016/j.jacc.2023.11.007>
- Malik VS, Willett WC, Hu FB. Nearly a decade on - trends, risk factors and policy implications in global obesity. *Nat Rev Endocrinol* 2020;**16**:615–6. <https://doi.org/10.1038/s41574-020-00411-y>
- NCD Risk Factor Collaboration (NCD-RisC). Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants. *Lancet* 2020;**396**:1511–24. [https://doi.org/10.1016/S0140-6736\(20\)31859-6](https://doi.org/10.1016/S0140-6736(20)31859-6)
- Mongraw-Chaffin ML, Peters SAE, Huxley RR, Woodward M. The sex-specific association between BMI and coronary heart disease: a systematic review and meta-analysis of 95 cohorts with 1.2 million participants. *Lancet Diabetes Endocrinol* 2015;**3**:437–49. [https://doi.org/10.1016/S2213-8587\(15\)00086-8](https://doi.org/10.1016/S2213-8587(15)00086-8)
- Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart Disease and Stroke Statistics-2021 update: a report from the American Heart Association. *Circulation* 2021;**143**:e254–743. <https://doi.org/10.1161/CIR.00000000000000950>
- Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al. European Society of Cardiology: cardiovascular disease statistics 2021. *Eur Heart J* 2022;**43**:716–99. <https://doi.org/10.1093/eurheartj/ehab892>
- Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. *Eur Heart J* 2021;**42**:4324–32. <https://doi.org/10.1093/eurheartj/ehab432>
- Schipper HS, de Ferranti S. Atherosclerotic cardiovascular risk as an emerging priority in pediatrics. *Pediatrics* 2022;**150**:e2022057956. <https://doi.org/10.1542/peds.2022-057956>
- Kivimaki M, Smith GD, Timpson NJ, Lawlor DA, Batty GD, Kahonen M, et al. Lifetime body mass index and later atherosclerosis risk in young adults: examining causal links using Mendelian randomization in the cardiovascular risk in young Finns study. *Eur Heart J* 2008;**29**:2552–60. <https://doi.org/10.1093/eurheartj/ehn252>
- EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Lancet* 2021;**398**:1713–25. [https://doi.org/10.1016/S0140-6736\(21\)01122-3](https://doi.org/10.1016/S0140-6736(21)01122-3)
- EAS Familial Hypercholesterolaemia Studies Collaboration; Vallejo-Vaz AJ, De Marco M, Stevens CAT, Akram A, Freiburger T, et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Atherosclerosis* 2018;**277**:234–55. <https://doi.org/10.1016/j.atherosclerosis.2018.08.051>

12. Representatives of the Global Familial Hypercholesterolemia Community; Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifawi M, et al. Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action. *JAMA Cardiol* 2020;**5**:217–29. <https://doi.org/10.1001/jamacardio.2019.5173>
13. Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. *J Am Coll Cardiol* 2020;**75**:2553–66. <https://doi.org/10.1016/j.jacc.2020.03.057>
14. Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. *Circulation* 2020;**141**:1742–59. <https://doi.org/10.1161/CIRCULATIONAHA.119.044795>
15. Dai H, Much AA, Maor E, Asher E, Younis A, Xu Y, et al. Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990–2017: results from the global burden of disease study 2017. *Eur Heart J Qual Care Clin Outcomes* 2022;**8**:50–60. <https://doi.org/10.1093/ehjcco/qcaa076>
16. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. *J Am Coll Cardiol* 2020;**76**:2982–3021. <https://doi.org/10.1016/j.jacc.2020.11.010>
17. Akioyamen LE, Genest J, Chu A, Inibhunu H, Ko DT, Tu JV. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: a systematic review and meta-analysis. *J Clin Lipidol* 2019;**13**:15–30. <https://doi.org/10.1016/j.jacl.2018.10.012>
18. Perez de Isla L, Alonso R, Mata N, Fernandez-Perez C, Muniz O, Diaz-Diaz JL, et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study). *Circulation* 2017;**135**:2133–44. <https://doi.org/10.1161/CIRCULATIONAHA.116.024541>
19. EAS Familial Hypercholesterolemia Studies Collaboration; Vallejo-Vaz AJ, Akram A, Kondapally Seshasai SR, Cole D, Watts GF, et al. Pooling and expanding registries of familial hypercholesterolemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS Familial Hypercholesterolemia Studies Collaboration. *Atheroscler Suppl* 2016;**22**:1–32. <https://doi.org/10.1016/j.atherosclerosis.2016.10.001>
20. World Health Organization. *WHO Factsheets: Obesity and Overweight 2021*. <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight> (May 2024, date last accessed).
21. World Health Organization. *BMI-for-age (5–19 years)*. <https://www.who.int/toolkits/growth-reference-data-for-5to19-years/indicators/bmi-for-age> (January 2024, date last accessed).
22. World Health Organization 2000. *The Asia-Pacific Perspective: Redefining Obesity and Its Treatment*. <https://iris.who.int/handle/10665/206936> (November 2024, date last accessed).
23. Schumacher D. *Anthroplus: Computation of the WHO 2007 References for School-Age Children and Adolescents (5 to 19 Years)*. R package version 0.9.0. <https://CRAN.R-project.org/package=anthroplus> (November 2024, date last accessed).
24. World Health Organization. *BMI-for-age z-score Tables (girls 5–19 years)*. [https://cdn.who.int/media/docs/default-source/child-growth/growth-reference-5-19-years/bmi-for-age-\(5-19-years\)/bmifa-girls-5-19-years-z.pdf?sfvrsn=8f7e5b11_4](https://cdn.who.int/media/docs/default-source/child-growth/growth-reference-5-19-years/bmi-for-age-(5-19-years)/bmifa-girls-5-19-years-z.pdf?sfvrsn=8f7e5b11_4) (January 2024, date last accessed).
25. World Health Organization. *BMI-for-age z-score Tables (boys 5–19 years)*. [https://cdn.who.int/media/docs/default-source/child-growth/growth-reference-5-19-years/bmi-for-age-\(5-19-years\)/bmifa-boys-5-19-years-z.pdf?sfvrsn=b74e5f9a_4](https://cdn.who.int/media/docs/default-source/child-growth/growth-reference-5-19-years/bmi-for-age-(5-19-years)/bmifa-boys-5-19-years-z.pdf?sfvrsn=b74e5f9a_4) (January 2024, date last accessed).
26. Won K-B, Heo R, Park H-B, Lee BK, Lin FY, Hadamitzky M, et al. Atherogenic index of plasma and the risk of rapid progression of coronary atherosclerosis beyond traditional risk factors. *Atherosclerosis* 2021;**324**:46–51. <https://doi.org/10.1016/j.atherosclerosis.2021.03.009>
27. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER/HDL). *Clin Biochem* 2001;**34**:583–8. [https://doi.org/10.1016/S0009-9120\(01\)00263-6](https://doi.org/10.1016/S0009-9120(01)00263-6)
28. Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, et al. Triglyceride-Rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. *Circulation* 2018;**138**:770–81. <https://doi.org/10.1161/CIRCULATIONAHA.117.032318>
29. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. *J Am Coll Cardiol* 2013;**61**:427–36. <https://doi.org/10.1016/j.jacc.2012.08.1026>
30. United Nations Statistics Division. *Standard Country or Area Codes for Statistical Use (M49)*. <https://unstats.un.org/unsd/methodology/m49> (January 2024, date last accessed).
31. The World Bank. *World Bank Country and Lending Groups 2024*. <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups> (January 2024, date last accessed).
32. Wood SN. Stable and efficient multiple smoothing parameter estimation for generalized additive models. *J Am Stat Assoc* 2004;**99**:673–86. <https://doi.org/10.1198/016214504000000980>
33. Watts GF, Gidding SS, Hegele RA, Raal FJ, Sturm AC, Jones LK, et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolemia. *Nat Rev Cardiol* 2023;**20**:845–69. <https://doi.org/10.1038/s41569-023-00892-0>
34. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. *Lancet* 2017;**390**:2627–42. [https://doi.org/10.1016/S0140-6736\(17\)32129-3](https://doi.org/10.1016/S0140-6736(17)32129-3)
35. Nussbaumerova B, Rosolova H. Obesity and dyslipidemia. *Curr Atheroscler Rep* 2023;**25**:947–55. <https://doi.org/10.1007/s11883-023-01167-2>
36. Miettinen TA, Gylling H. Cholesterol absorption efficiency and sterol metabolism in obesity. *Atherosclerosis* 2000;**153**:241–8. [https://doi.org/10.1016/S0021-9150\(00\)00404-4](https://doi.org/10.1016/S0021-9150(00)00404-4)
37. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration; Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. *Lancet* 2014;**383**:970–83. [https://doi.org/10.1016/S0140-6736\(13\)61836-X](https://doi.org/10.1016/S0140-6736(13)61836-X)
38. Kwaifia IK, Bahari H, Yong YK, Noor SM. Endothelial dysfunction in obesity-induced inflammation: molecular mechanisms and clinical implications. *Biomolecules* 2020;**10**:291. <https://doi.org/10.3390/biom10020291>
39. Jebari-Benslaiman S, Galicia-Garcia U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, et al. Pathophysiology of atherosclerosis. *Int J Mol Sci* 2022;**23**:3346. <https://doi.org/10.3390/ijms23063346>
40. Henning RJ. Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity. *Am J Cardiovasc Dis* 2021;**11**:504–29. <https://pubmed.ncbi.nlm.nih.gov/34548951/>
41. Lopez-Domenech S, Martinez-Herrera M, Abad-Jimenez Z, Morillas C, Escribano-Lopez I, Diaz-Morales N, et al. Dietary weight loss intervention improves subclinical atherosclerosis and oxidative stress markers in leukocytes of obese humans. *Int J Obes (Lond)* 2019;**43**:2200–9. <https://doi.org/10.1038/s41366-018-0309-5>
42. Pack QR, Rodriguez-Escudero JP, Thomas RJ, Ades PA, West CP, Somers VK, et al. The prognostic importance of weight loss in coronary artery disease: a systematic review and meta-analysis. *Mayo Clin Proc* 2014;**89**:1368–77. <https://doi.org/10.1016/j.mayocp.2014.04.033>
43. Sutanto A, Wungu CDK, Susilo H, Sutanto H. Reduction of Major adverse cardiovascular events (MACE) after bariatric surgery in patients with obesity and cardiovascular diseases: a systematic review and meta-analysis. *Nutrients* 2021;**13**:3568. <https://doi.org/10.3390/nu13103568>
44. Chung ST, Krenek A, Magge SN. Childhood obesity and cardiovascular disease risk. *Curr Atheroscler Rep* 2023;**25**:405–15. <https://doi.org/10.1007/s11883-023-01111-4>
45. Jebile H, Kelly AS, O'Malley G, Baur LA. Obesity in children and adolescents: epidemiology, causes, assessment, and management. *Lancet Diabetes Endocrinol* 2022;**10**:351–65. [https://doi.org/10.1016/S2213-8587\(22\)00047-X](https://doi.org/10.1016/S2213-8587(22)00047-X)
46. Mangner N, Scheuermann K, Winzer E, Wagner I, Hoellriegel R, Sandri M, et al. Childhood obesity: impact on cardiac geometry and function. *JACC Cardiovasc Imaging* 2014;**7**:1198–205. <https://doi.org/10.1016/j.jcmg.2014.08.006>
47. Gjaerde LK, Gamborg M, Angquist L, Truelsen TC, Sorensen TIA, Baker JL. Association of childhood body mass index and change in body mass index with first adult ischemic stroke. *JAMA Neurol* 2017;**74**:1312–8. <https://doi.org/10.1001/jamaneurol.2017.1627>
48. European Atherosclerosis Society Familial Hypercholesterolemia Studies Collaboration. Familial hypercholesterolemia in children and adolescents from 48 countries: a cross-sectional study. *Lancet* 2024;**403**:55–66. [https://doi.org/10.1016/S0140-6736\(23\)01842-1](https://doi.org/10.1016/S0140-6736(23)01842-1)
49. McMahan CA, Gidding SS, McGill HC Jr. Coronary heart disease risk factors and atherosclerosis in young people. *J Clin Lipidol* 2008;**2**:118–26. <https://doi.org/10.1016/j.jacl.2008.02.006>
50. Besseling J, Kindt I, Hof M, Kastelein JJ, Hutten BA, Hovingh GK. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. *Atherosclerosis* 2014;**233**:219–23. <https://doi.org/10.1016/j.atherosclerosis.2013.12.020>
51. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolemia: data in 2400 patients. *J Intern Med* 2004;**256**:482–90. <https://doi.org/10.1111/j.1365-2796.2004.01405.x>
52. Gaudet D, Vohl MC, Perron P, Tremblay G, Gagne C, Lesiege D, et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. *Circulation* 1998;**97**:871–7. <https://doi.org/10.1161/01.CIR.97.9.871>
53. Trinder M, Vikulova D, Pimstone S, Mancini GB, Brunham LR. Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia. *Atherosclerosis* 2022;**340**:35–43. <https://doi.org/10.1016/j.atherosclerosis.2021.11.032>